L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin

被引：35

作者：

Clair T. ^{[1
]}

Koh E. ^{[1
]}

Ptaszynska M. ^{[1
]}

Bandle R.W. ^{[1
]}

Liotta L.A. ^{[1
]}

Schiffmann E. ^{[1
]}

Stracke M.L. ^{[1
]}

机构：

[1] Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda

来源：

Lipids in Health and Disease | / 4卷 / 1期

关键词：

Histidine; A2058 Cell; Metal Cation; Motility Assay; Histidinol;

D O I：

10.1186/1476-511X-4-5

中图分类号：

学科分类号：

摘要：

Background: Autotaxin (ATX, NPP-2), originally purified as a potent tumor cell motility factor, is now known to be the long-sought plasma lysophospholipase D (LPLD). The integrity of the enzymatic active site, including three crucial histidine moieties, is required for motility stimulation, as well as LPLD and 5′nucleotide phosphodiesterase (PDE) activities. Except for relatively non-specific chelation agents, there are no known inhibitors of the ATX LPLD activity. Results: We show that millimolar concentrations of L-histidine inhibit ATX-stimulated but not LPA-stimulated motility in two tumor cell lines, as well as inhibiting enzymatic activities. Inhibition is reversed by 20-fold lower concentrations of zinc salt. L-histidine has no significant effect on the Km of LPLD, but reduces the Vmax by greater than 50%, acting as a non-competitive inhibitor. Several histidine analogs also inhibit the LPLD activity of ATX; however, none has greater potency than L-histidine and all decrease cell viability or adhesion. Conclusion: L-histidine inhibition of LPLD is not a simple stoichiometric chelation of metal ions but is more likely a complex interaction with a variety of moieties, including the metal cation, at or near the active site. The inhibitory effect of L-histidine requires all three major functional groups of histidine: the alpha amino group, the alpha carboxyl group, and the metal-binding imidazole side chain. Because of LPA's involvement in pathological processes, regulation of its formation by ATX may give insight into possible novel therapeutic approaches. © 2005 Clair et al; licensee BioMed Central Ltd.

引用

共 35 条

[1]

Umezu-Goto M., Tanyi J., Lahad J., Liu S., Yu S., Lapushin R., Hasegawa Y., Lu Y., Trost R., Bevers T., Jonasch E., Aldape K., Liu J., James R.D., Ferguson C.G., Xu Y., Prestwich G.D., Mills G.B., Lysophosphatidic acid production and action: Validated targets in cancer?, J Cell Biochem, 92, 6, pp. 1115-1140, (2004)

[2]

Aoki J., Taira A., Takanezawa Y., Kishi Y., Hama K., Kishimoto T., Mizuno K., Saku K., Taguchi R., Arai H., Serum lysophosphatidic acid is produced through diverse phospholipase pathways, J Biol Chem, 277, 50, pp. 48737-48744, (2002)

[3]

Sano T., Baker D., Virag T., Wada A., Yatomi Y., Kobayashi T., Igarashi Y., Tigyi G., Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood, J Biol Chem, 277, 24, pp. 21197-21206, (2002)

[4]

Tokumura A., Majima E., Kariya Y., Tominaga K., Kogure K., Yasuda K., Fukuzawa K., Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase, J Biol Chem, 277, 42, pp. 39436-39442, (2002)

[5]

Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., Yamori T., Mills G.B., Inoue K., Aoki J., Arai H., Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production, J Cell Biol, 158, 2, pp. 227-233, (2002)

[6]

Stracke M.L., Krutzsch H.C., Unsworth E.J., Arestad A., Cioce V., Schiffmann E., Liotta L.A., Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein, J Biol Chem, 267, 4, pp. 2524-2529, (1992)

[7]

Koh E., Clair T., Woodhouse E.C., Schiffmann E., Liotta L., Stracke M., Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities, Cancer Res, 63, 9, pp. 2042-2045, (2003)

[8]

Hama K., Aoki J., Fukaya M., Kishi Y., Sakai T., Suzuki R., Ohta H., Yamori T., Watanabe M., Chun J., Arai H., Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1, J Biol Chem, 279, 17, pp. 17634-17639, (2004)

[9]

Clair T., Aoki J., Koh E., Bandle R.W., Nam S.W., Ptaszynska M.M., Mills G.B., Schiffmann E., Liotta L.A., Stracke M.L., Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate, Cancer Res, 63, 17, pp. 5446-5453, (2003)

[10]

Okamoto H., Takuwa N., Yokomizo T., Sugimoto N., Sakurada S., Shigematsu H., Takuwa Y., Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3, Mol Cell Biol, 20, 24, pp. 9247-9261, (2000)

← 1 2 3 4 →